Phase 1 clinical studies require very good organization from the very beginning. The budget is used quickly, safety decisions are sensitive, and any delay pushes all the following stages forward. That is why planning starts when the sponsor defines the study objective, the population and the acceptable level of risk.
In practice, Phase 1 clinical trials put pressure on three things at the same time: budget, time and operational control. These studies usually include First-in-Human, SAD, MAD, bioequivalence, bioavailability, drug-drug interaction or food effect studies. All of them are conducted in specialized clinical units and under strict regulatory requirements.
How the budget is built in a Phase 1 study
A good budget starts with the type of study and the level of risk. A First-in-Human study requires stricter monitoring and safety measures. A bioequivalence study has a more predictable design and costs are easier to estimate.
Many sponsors calculate only the fee paid to the CRO or to the clinical site. In reality, the total cost also includes the sponsor’s internal resources, document reviews, approval delays, protocol amendments and rescheduling. In Phase 1 clinical trials, these elements have a major impact on the final budget.
The main cost categories usually include:
- protocol development and scientific consulting;
- regulatory submissions and ethics approvals;
- clinical unit costs and medical staff;
- recruitment and volunteer compensation;
- bioanalytical testing and PK/PD sample processing;
- data management, biostatistics and final report;
- contingency budget for amendments and delays.
An experienced sponsor usually works with two budgets: the base budget and the contingency budget. The contingency budget helps control unexpected situations. If the study includes multiple cohorts, dose escalation or strict inclusion criteria, this reserve becomes very important.
The operational partner also plays an important role. A full-service CRO can reduce time lost between stages. When study design, regulatory submissions, clinical conduct, bioanalysis and reporting are coordinated in one place, costs are easier to control.
In Phase 1 clinical trials, infrastructure is extremely important for participant safety and data quality.
Study planning directly influences costs and timelines
Many sponsors try to shorten the timeline as much as possible. In reality, an overly optimistic plan leads to delays. And delays always mean more time and higher costs.
Proper planning starts with a few simple questions:
- what exactly the sponsor wants to learn from the study;
- what type of participants are needed;
- how many cohorts are required;
- what monitoring periods are mandatory;
- what results are needed to move to the next development stage.
After these points are defined, the full study plan can be built. The plan must include all stages, not just the period when participants are admitted to the clinic. It must include protocol writing, approvals, bioanalytical method validation, logistics, screening, admission, dosing, sample collection, data analysis and the final report.
Recruitment is one of the most sensitive stages. Final participant eligibility is also critical. If the study has strict inclusion criteria, recruitment may take longer. That is why it is important for the clinical unit to have volunteer databases and recruitment experience for Phase 1 clinical studies.
Specialized clinical research units can manage SAD, MAD, food effect, drug-drug interaction and First-in-Human studies more efficiently. Continuous monitoring, permanent medical staff and electronic data capture systems help keep the study on schedule and reduce delays.
Risk management in a Phase 1 study
In Phase 1 clinical trials, participant safety is the main priority. At the same time, the sponsor must manage operational risks, regulatory risks, data quality risks and financial risks.
A practical approach is to perform a risk analysis for each stage of the study. The team should identify what can happen, how likely it is and what impact it may have. Then, concrete mitigation measures should be defined.
The most common risks include:
- slower recruitment than expected;
- participants who fail screening;
- protocol deviations;
- adverse reactions that require stopping dose escalation;
- sample processing issues;
- approval delays;
- differences between the plan and the operational reality.
Each risk should have a clear mitigation plan. For recruitment, active volunteer databases and strong relationships with referring physicians help. For safety, continuous monitoring, emergency equipment and permanent medical staff are essential. For data quality, electronic data capture systems and dedicated PK/PD laboratories that process samples quickly are very important.
Regulatory risk is also very important. The study must comply with international standards and regulatory requirements. If the study is inspected, the documentation and procedures must be in order. That is why the experience of the clinical unit and compliance with ICH-GCP standards are extremely important for the sponsor.
Choosing the right partner for the study
Choosing the right partner directly affects costs, timelines and study quality. Price is important, but it is not the only factor. In Phase 1 trials, experience and organizational capacity matter the most.
A sponsor should evaluate several key aspects:
- experience in Phase 1 clinical studies;
- clinical infrastructure and medical equipment;
- participant recruitment capabilities;
- availability of bioanalytical laboratories;
- statistics and reporting services;
- inspection history and quality standards;
- communication and project management.
A good partner provides realistic timelines and explains potential risks from the beginning. Good communication between the sponsor and the study team helps solve problems quickly. In Phase 1 clinical trials, decisions often need to be made quickly, and teams must work in a coordinated way.
When the budget is well structured, the plan is realistic and risks are managed early, the study can run smoothly. The sponsor obtains reliable data and can move forward to the next stages of clinical development. This means a well-organized study and a strong foundation for future drug development.
